Indian biopharmaceutical company Biocon Limited (NSE:BIOCON) is seeking a partner to test generic versions of Novo Nordisk's (CPH:NOVO-B) diabetes drug Ozempic and weight loss treatment Wegovy in China, Reuters reported on Thursday.
An unnamed senior executive told the news agency that Biocon is looking for a Chinese partner for clinical trials on patients in order to sell the drug in China.
Biocon is aiming to launch generic versions of the drugs globally.
Patent protection on semaglutide, a key ingredient in both Ozempic and Wegovy, is due to expire in China in early 2026.
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules
Dexcel Pharma's Nintedanib Capsules approved for US launch
Upsher-Smith launches generic version of Ciprodex ear drop suspension
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
Breckenridge Pharmaceutical partners with sterile injectable manufacturer Maiva Pharma
Breckenridge Pharmaceutical launches Pomalidomide Capsules in US market
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval
Viatris names new chief legal officer
Alvotech signs biosimilar supply and commercialisation deals with Sandoz
InSysBio agrees new collaborative project with BeOne Medicines